Key Highlights
- Loss per share of USD 0.07 was wider than the USD 0.06 estimate, and the company reported no revenue.
- Net loss was USD 14.62 million against USD 2.87 million, and nine-month net loss was USD 34.80 million.
- Nine-month stock-based compensation and related charges were USD 14.15 million against USD 228,000 a year earlier.
- Weighted average shares were 212.0 million against 7.5 million a year earlier, which affects per share comparisons.
Palisade Bio, Inc. (NASDAQ:PALI), a clinical-stage biopharmaceutical company, reported a third quarter 2026 loss of USD 0.07 per share against an estimated loss of USD 0.06 and USD 0.38 a year earlier. The company reported no Revenue in the quarter. Net loss was USD 14.62 million against USD 2.87 million.
For the nine months, net loss was USD 34.80 million, or USD 0.16 per share, against USD 7.88 million, or USD 1.38 per share. Total other income, net was USD 1.08 million against USD 54,000 for the quarter.
Operating Expenses
Research and development expense was USD 10.58 million against USD 1.39 million, and general and administrative expense was USD 5.12 million against USD 1.53 million. Total operating expenses were USD 15.70 million against USD 2.92 million, and loss from operations was USD 15.70 million against USD 2.92 million.
For the nine months, Research and Development expense was USD 24.38 million and general and administrative expense was USD 14.27 million, for total operating expenses of USD 38.65 million and a loss from operations of USD 38.15 million.
License Revenue and Equity Items
Basic and diluted weighted average shares were 212.03 million against 7.47 million for the quarter, and 211.04 million against 5.70 million for the nine months. Nine-month Cash Flow adjustments included stock-based compensation and related charges of USD 14.15 million against USD 228,000, and a USD 75,000 write-off of deferred equity issuance costs in the prior year.
The filing states the company recognized license revenue of USD 0.5 million in the nine months, earned in the second quarter of 2026 when Newsoara achieved a development milestone under the Newsoara Co-Development Agreement. It recognized no license revenue from that agreement in the third quarter of 2026 or in the 2025 periods.
The filing also states the underlying common shares for the unexercised portion of pre-funded common stock warrants from an October 2025 offering are included in the denominator for basic and diluted net loss per share. It says deferred equity issuance costs consist of legal, accounting and other direct costs attributable to a shelf registration statement on Form S-3, and that in 2025 the company expensed about USD 75,000 of previously deferred costs after an earlier shelf registration expired in April 2025.
Changes in operating Assets and liabilities included a USD 4.22 million increase in prepaid and other assets and a USD 2.15 million increase in Accounts Payable and accrued liabilities, which together bear on the company's cash use during the nine month period.
Items to Follow
The items to follow are research and development spending, stock-based compensation, license milestones and the cash balance.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...